Back to search results

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Blood Cancers

This study is looking at how whole brain radiation therapy (WBRT) affects memory and thinking (neurocognitive outcomes) in people with blood cancers like lymphoma, leukemia, and myeloma. Researchers will use standard tests to measure your cognitive abilities, quality of life, and look at changes in your brain using MRI scans. They will also explore the role of a medication called Memantine in cognitive outcomes. The main goal is to understand the long-term effects of WBRT on thinking skills. You can join if you are 18 or older, have received WBRT for a blood cancer, and can complete tests in English. The study aims to enroll 100 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning participants will be monitored without receiving a specific study treatment. It plans to include 100 participants.
What's involved
You would undergo neurocognitive function assessments, complete questionnaires, and have MRI scans at baseline, 2, 6, and 12 months after radiation, then yearly for 5 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 5 years after radiation therapy completion to assess cognitive outcomes.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05011045

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Recruiting
Not specifiedAges 18+Observational
M.D. Anderson Cancer Center
~100 participants
Updated 2026-05-20 on ClinicalTrials.gov
What's tested:Magnetic Resonance ImagingNeurocognitive AssessmentQuality-of-Life AssessmentQuestionnaire Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cognitive outcomes
Measured over Up to 5 years

Conditions

Central Nervous System Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Leukemia
Lymphoma
Plasma Cell Myeloma
Secondary Central Nervous System Lymphoma

Explore related trials

Central Nervous System LymphomaHematologic NeoplasmLeukemiaLymphomaMultiple Myeloma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Bouthaina S Dabaja · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Dustin M Silk
[email protected]@mdanderson.org
713-563-3090
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18 years or older
Treatment with radiation therapy to the brain for a hematologic malignancy (ex. primary central nervous system lymphoma \[PCNSL\], secondary central nervous system lymphoma \[SCNSL\], leukemia, myeloma)
Proficient and capable of completing tests in English
Patients with claustrophobia are eligible if the claustrophobia is managed with medication
Patients with cognitively-impairment are eligible if the impairment is managed with medication
Patients who are pregnant

What this trial measures

  • Cognitive outcomesUp to 5 years

    Neurocognitive failure will be defined as the first cognitive failure on 2 or more of the following tests: the Hopkins Verbal Learning Test Revised Total Recall, Delayed Recall and Delayed Recognition; the Controlled Oral Word Association; and the Trail Making Test Part A or B. The rate of neurocognitive failure and its 95% confidence interval (CI) will be calculated. The cumulative incidence approach may be used to estimate the median time to neurocognitive failure to account for the competing risk of death. May use the Aalen-Johansen estimator of the cumulative incidence function.